FAKTOR-OPTIONSSCHEIN - UNITED THERAPEUTICS Share Price

Certificat

DE000MG0JS89

Market Closed - Börse Stuttgart 11:28:40 31/05/2024 pm IST
17.19 EUR +1.30% Intraday chart for FAKTOR-OPTIONSSCHEIN - UNITED THERAPEUTICS
Current month+92.50%
1 month+92.50%
Date Price Change
31/24/31 17.19 +1.30%
30/24/30 16.97 +12.98%
29/24/29 15.02 -18.72%
28/24/28 18.48 +1.20%
27/24/27 18.26 -6.26%

Delayed Quote Börse Stuttgart

Last update May 31, 2024 at 11:28 pm IST

More quotes

Static data

Product typeProduits Exotiques
Buy / SellCALL
Underlying UNITED THERAPEUTICS CORPORATION
Issuer Morgan Stanley
WKN MG0JS8
ISINDE000MG0JS89
Date issued 20/03/2024
Strike 225.4 $
Maturity Unlimited
Parity 2.48 : 1
Emission price 10
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 20.4
Lowest since issue 7.62
Spread 0.29
Spread %1.54%

Company Profile

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Sector
-
More about the company

Ratings for United Therapeutics Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: United Therapeutics Corporation

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
275.1 USD
Average target price
294.2 USD
Spread / Average Target
+6.92%
Consensus